生技药品市场规模、份额及成长分析（按类型、药物类别、治疗用途、来源、製造业及地区）－2025-2032 年产业预测

2023 年生技药品市场规模价值为 5,113 亿美元，预计将从 2024 年的 5,675.4 亿美元成长到 2032 年的 1,3079.2 亿美元，预测期内（2025-2032 年）的复合年增长率为 11.0%。

受生物技术进步和标靶治疗需求不断增长的推动，全球生技药品市场呈现强劲成长。生技药品，即从生物来源中提取的药物化合物，彻底改变了癌症、自体免疫疾病和感染疾病等慢性疾病的治疗模式。他们的客製化创新方法改善了患者的治疗效果，并将生物製药定位为现代医疗保健的关键组成部分。市场成长的主要驱动力是糖尿病和关节炎等慢性疾病的日益流行，这反过来又需要有效的治疗方案。然而，由于这些生技药品会受到温度和环境条件的影响，因此在整个供应链中维持其完整性仍然存在挑战。美国生技药品市场预计将持续成长，展现出生物製药在改善生活品质和控制疾病方面的巨大潜力。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析

生技药品市场规模（按类型）

• 市场概览
• 肿瘤坏死因子（TNF）抑制剂
• T细胞抑制剂
• 选择性共刺激调节剂
• 白细胞介素-6 (IL-6) 或白细胞介素-17 阻断剂
• 白细胞介素-1（IL-1）阻断剂
• B细胞抑制剂

生技药品市场规模（依药物类别）

• 市场概览
• 单株抗体
• 重组胰岛素
• 疫苗
• 血液因素
• 人体生长荷尔蒙
• 促红血球生成素
• 融合蛋白
• 重组酵素
• 干扰素
• 集落刺激因子
• 基因治疗
  • 细胞疗法
  • 寡核苷酸
  • 其他的
• 胜肽
• 肉毒桿菌毒素
• 其他的

生技药品市场规模（依治疗用途划分）

• 市场概览
• 肿瘤学
• 自体免疫疾病/免疫疾病
• 代谢紊乱
• 眼科疾病
• 呼吸系统疾病
• 发炎性肠道疾病（IBD）
• 神经系统疾病
• 心血管疾病（CVD）
• 肌肉骨骼疾病（MSD）
• 感染疾病
• 其他的

生技药品市场规模（依来源）

• 市场概览
• 微生物
• 哺乳动物
• 其他的

按製造业分類的生技药品市场规模

• 市场概览
• 外包
• 内部製造

生技药品市场规模（依药物类型划分）

• 市场概览
• 品牌药物
• 学名药

以采购方式生技药品市场规模

• 市场概览
• 处方药
• 场外交易（OTC）

生技药品市场规模（以剂型划分）

• 市场概览
• 注射
• 锭剂
• 其他的

生技药品市场规模（依给药途径）

• 市场概览
• 肠外
• 口服
• 其他的

生技药品市场规模（以最终用户划分）

• 市场概览
• 医院
• 专科诊所
• 居家护理
• 其他的

生技药品市场规模（按分销管道）

• 市场概览
• 医院药房
• 零售药局
• 网路药局
• 其他的

生技药品市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Roche Holding AG（Switzerland）
• Johnson & Johnson（USA）
• AbbVie Inc.（USA）
• Novartis AG（Switzerland）
• Amgen Inc.（USA）
• Merck & Co., Inc.（USA）
• Bristol Myers Squibb（USA）
• Eli Lilly and Company（USA）
• AstraZeneca plc（UK）
• Biogen Inc.（USA）
• Gilead Sciences, Inc.（USA）
• Regeneron Pharmaceuticals, Inc.（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• Boehringer Ingelheim（Germany）
• Samsung Biologics（South Korea）
• Lonza Group AG（Switzerland）
• WuXi Biologics（China）
• Celltrion, Inc.（South Korea）
• Grifols, SA（Spain）

结论和建议

Biologics Market size was valued at USD 511.3 billion in 2023 and is poised to grow from USD 567.54 billion in 2024 to USD 1307.92 billion by 2032, growing at a CAGR of 11.0% during the forecast period (2025-2032).

The global biologics market has demonstrated robust growth, driven by advancements in biotechnology and the rising demand for targeted therapies. Biologics, pharmaceutical compounds sourced from living organisms, have shifted the landscape of treatment for chronic conditions, including cancer, autoimmune disorders, and infectious diseases. Their tailored and innovative approaches enhance patient outcomes, positioning biopharmaceuticals as critical components in modern healthcare. Key market growth drivers include the escalating prevalence of chronic diseases, such as diabetes and arthritis, necessitating effective treatment options. However, challenges remain in maintaining the integrity of these biologics throughout the supply chain, influenced by temperature and environmental conditions. The US biologics market is set for sustained growth, indicating promising prospects for biopharmaceuticals in improving quality of life and disease management.

Top-down and bottom-up approaches were used to estimate and validate the size of the Biologics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Biologics Market Segments Analysis

Global Biologics Market is segmented by Type, Drug Class, Therapeutic Application, Source, Manufacturing, Drug Type, Mode of Purchase, Dosage Form, Route of Administration, End-Users, Distribution Channel and region. Based on Type, the market is segmented into Tumor Necrosis Factor (TNF) Inhibitor, T-cell Inhibitor, Selective Co-stimulation Modulators, Interleukin-6 (IL-6) or Interleukin-17 Blocker, Interleukin-1 (IL-1) Blocker and B-cell Inhibitor. Based on Drug Class, the market is segmented into Monoclonal Antibody, Recombinant Insulin, Vaccine, Blood Factor, Human Growth Hormone, Erythropoietin, Fusion Protein, Recombinant Enzyme, Interferon, Colony-stimulating Factor, Gene Therapy, Peptide, Botulinum Toxin and Others. Based on Therapeutic Application, the market is segmented into Oncology, Autoimmune/Immunologic Diseases, Metabolic Disorders, Ophthalmic Diseases, Respiratory Disorders, Inflammatory Bowel Diseases (IBDs), Neurological Disorders, Cardiovascular Diseases (CVDs), Musculoskeletal Disorders (MSDs), Infectious Diseases and Others. Based on Source, the market is segmented into Microbial, Mammalian and Others. Based on Manufacturing, the market is segmented into Outsourced and In-House. Based on Drug Type, the market is segmented into Branded Drugs and Generic Drugs. Based on Mode of Purchase, the market is segmented into Prescription Drugs and Over-The-Counter (OTC) Drugs. Based on Dosage Form, the market is segmented into Injection, Tablets and Others. Based on Route of Administration, the market is segmented into Parenteral, Oral and Others. Based on End-Users, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Biologics Market

The rising prevalence of chronic diseases, including cancer, diabetes, and autoimmune disorders, has significantly spurred the demand for innovative biological therapies. These advanced treatments leverage targeted approaches, distinguishing them from traditional chemical-based medications and enhancing their effectiveness. As a result, the biologics market is experiencing substantial growth, driven by the need for more precise and efficient therapeutic options. This trend reflects a broader shift toward personalized medicine, where tailored treatments not only improve patient outcomes but also foster ongoing advancements in biopharmaceutical research and development, further propelling the market forward.

Restraints in the Biologics Market

The biologics market faces significant challenges due to the intricate and expensive processes involved in the development and production of natural products. The stringent regulatory standards in place can limit both the affordability and accessibility of biologic therapies, ultimately hindering market growth. As companies navigate these challenges, the high costs associated with compliance and manufacturing may deter investment and innovation, which could further stifle advancements in biologic treatments. Consequently, the interplay between regulatory demands and production complexities remains a critical restraint for the biologics market, impacting its overall potential and reach in the healthcare industry.

Market Trends of the Biologics Market

The Biologics market is witnessing a significant shift towards personalized medicine, fundamentally transforming therapeutic approaches. This trend emphasizes the development of biologic therapies tailored to the unique genetic profiles and specific disease characteristics of individual patients, leading to more effective and targeted treatments. As a result, innovation in biological sciences is accelerating, with advancements in areas such as monoclonal antibodies, gene therapies, and regenerative medicine. The growing demand for precision therapies is propelling investments and research in this field, expanding the scope and applications of biologics in managing various diseases, thus positioning the market for robust growth in the coming years.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Biologics Market Size by Type & CAGR (2025-2032)

• Market Overview
• Tumor Necrosis Factor (TNF) Inhibitor
• T-cell Inhibitor
• Selective Co-stimulation Modulators
• Interleukin-6 (IL-6) or Interleukin-17 Blocker
• Interleukin-1 (IL-1) Blocker
• B-cell Inhibitor

Global Biologics Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Monoclonal Antibody
• Recombinant Insulin
• Vaccine
• Blood Factor
• Human Growth Hormone
• Erythropoietin
• Fusion Protein
• Recombinant Enzyme
• Interferon
• Colony-stimulating Factor
• Gene Therapy
  • Cell Therapy
  • Oligonucleotides
  • Others
• Peptide
• Botulinum Toxin
• Others

Global Biologics Market Size by Therapeutic Application & CAGR (2025-2032)

• Market Overview
• Oncology
• Autoimmune/Immunologic Diseases
• Metabolic Disorders
• Ophthalmic Diseases
• Respiratory Disorders
• Inflammatory Bowel Diseases (IBDs)
• Neurological Disorders
• Cardiovascular Diseases (CVDs)
• Musculoskeletal Disorders (MSDs)
• Infectious Diseases
• Others

Global Biologics Market Size by Source & CAGR (2025-2032)

• Market Overview
• Microbial
• Mammalian
• Others

Global Biologics Market Size by Manufacturing & CAGR (2025-2032)

• Market Overview
• Outsourced
• In-House

Global Biologics Market Size by Drug Type & CAGR (2025-2032)

• Market Overview
• Branded Drugs
• Generic Drugs

Global Biologics Market Size by Mode of Purchase & CAGR (2025-2032)

• Market Overview
• Prescription Drugs
• Over-The-Counter (OTC) Drugs

Global Biologics Market Size by Dosage Form & CAGR (2025-2032)

• Market Overview
• Injection
• Tablets
• Others

Global Biologics Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Parenteral
• Oral
• Others

Global Biologics Market Size by End-Users & CAGR (2025-2032)

• Market Overview
• Hospitals
• Specialty Clinics
• Homecare
• Others

Global Biologics Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Global Biologics Market Size & CAGR (2025-2032)

• North America (Type, Drug Class, Therapeutic Application, Source, Manufacturing, Drug Type, Mode of Purchase, Dosage Form, Route of Administration, End-Users, Distribution Channel)
  • US
  • Canada
• Europe (Type, Drug Class, Therapeutic Application, Source, Manufacturing, Drug Type, Mode of Purchase, Dosage Form, Route of Administration, End-Users, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Drug Class, Therapeutic Application, Source, Manufacturing, Drug Type, Mode of Purchase, Dosage Form, Route of Administration, End-Users, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Drug Class, Therapeutic Application, Source, Manufacturing, Drug Type, Mode of Purchase, Dosage Form, Route of Administration, End-Users, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Drug Class, Therapeutic Application, Source, Manufacturing, Drug Type, Mode of Purchase, Dosage Form, Route of Administration, End-Users, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Biologics (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lonza Group AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi Biologics (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celltrion, Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols, S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations